Filing Details

Accession Number:
0001209191-19-001606
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-01-03 20:58:52
Reporting Period:
2018-12-31
Accepted Time:
2019-01-03 20:58:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1567514 Intra-Cellular Therapies Inc. ITCI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1521548 Michael Halstead C/O Intra-Cellular Therapies, Inc.
430 East 29Th Street
New York NY 10016
Evp And General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-12-31 7,807 $0.00 7,998 No 4 A Direct
Common Stock Disposition 2019-01-02 7,807 $11.09 191 No 4 S Direct
Common Stock Acquisiton 2019-01-03 5,298 $0.00 5,489 No 4 M Direct
Common Stock Acquisiton 2019-01-03 16,160 $0.00 21,649 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2019-01-03 5,298 $0.00 5,298 $0.00
Common Stock Restricted Stock Units Disposition 2019-01-03 16,160 $0.00 16,160 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
5,298 No 4 M Direct
32,320 No 4 M Direct
Footnotes
  1. Represents shares issued upon the vesting of performance stock units.
  2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2018. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.77 to $11.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. Restricted stock units convert into common stock on a one-for-one basis.
  5. Each restricted stock unit represents a contingent right to receive one share of common stock.
  6. On January 3, 2017, the reporting person was granted 15,893 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
  7. On January 3, 2018, the reporting person was granted 48,480 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.